Cetuximab With Concurrent Chemoradiation for Esophagogastric Cancer: Assessment of Toxicity

International Journal of Radiation Oncology Biology Physics

Volumn 70, Issue 2, 2008, Pages 391-395

  Safran, Howard ^a   Suntharalingam, Mohan ^b   Dipetrillo, Thomas ^a   Ng, Thomas ^a   Doyle, L Austin ^a,c   Krasna, Mark ^b   Plette, Angela ^a   Evans, Devon ^a   Wanebo, Harold ^a   Akerman, Paul ^a   Spector, Jeremy ^a   Kennedy, Nancy ^a   Kennedy, Teresa ^a  

^a Brown University Oncology Group   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Cetuximab; Esophageal cancer; Radiation

Indexed keywords

BIOLOGICAL ORGANS; CHEMOTHERAPY; RADIATION EFFECTS; TUMORS;

CETUXIMAB; ESOPHAGEAL CANCER;

TOXICITY;

CARBOPLATIN; CETUXIMAB; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

ACNE; ADENOCARCINOMA; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG FATALITY; DRUG HYPERSENSITIVITY; ESOPHAGITIS; ESOPHAGUS CANCER; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE; RADIATION FIELD; RASH; SIDE EFFECT; SKIN PRURITUS; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; DRUG HYPERSENSITIVITY; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS; FACIAL DERMATOSES; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; STOMACH NEOPLASMS;

EID: 38149088836     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.07.2325     Document Type: Article

References (28)

1. Herskovic A., Martz K., Al-Sarraf M., et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326 (1992) 1593-1598
2. Minsky B.D., Pajak T.F., Ginsberg R.J., et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 20 (2002) 1167-1174
3. Ilson D.H. Cancer of the gastroesophageal junction: current therapy options. Curr Treat Options Oncol 7 (2006) 410-423
4. Ng T., Dipetrillo T., Purviance J., et al. Multi-modality treatment of esophageal cancer: A review of the current status and future directions. Curr Oncol Rep 8 (2006) 174-182
5. Mendelsohn J., Baird A., Fan Z., et al. Growth factors and their receptors in epithelial malignancies. In: Mendelsohn J., Howley P.M., Israel M.A., and Liotta L.A. (Eds). The molecular basis of cancer (2001), W.B. Saunders Company, Philadelphia, PA 137-144
6. Huang S.M., and Harari P.M. Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale and preliminary clinical results. Invest New Drugs 17 (1999) 259-269
7. Ozawa S., Ueda M., Ando N., et al. Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinoma. Cancer 63 (1989) 2169-2173
8. Makuda H., Toi M., Hirai T., et al. Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer 68 (1991) 142-148
9. Hickey K., Grehan D., Reid I.M., et al. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous carcinoma to chemoradiotherapy. Cancer 74 (1994) 1693-1698
10. Gibson M.K., Abraham S.C., Wu T.T., et al. Epidermal growth factor receptor, p53 mutation and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemotherapy. Clin Ca Res 9 (2003) 6461-6468
11. Wu X., Fan Z., Masui H., et al. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95 (1995) 1897-1905
12. Raben D., Helfrich B., and Bunn P.A. Targeted therapies for non-small-cell lung cancer: Biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys 59 Suppl (2004) 27-38
13. Langer C.J. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: Focus on NSCLC. Int J Radiat Oncol Biol Phys 58 (2004) 991-1002
14. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma for the head and neck. N Engl J Med 354 (2006) 567-578
15. Pfister D.G., Su Y.B., Kraus D.H., et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined modality paradigm. J Clin Oncol 24 (2006) 1072-1078
16. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
17. Saltz L., Meropol N.J., and Loehrer P.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 (2004) 1201-1208
18. Safran H., Gaissert H., Akerman P., et al. Paclitaxel, cisplatin and concurrent radiation for esophageal cancer. Cancer Invest 1 (2001) 1-7
19. Safran H., DiPetrillo T., Akerman P., et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 67 (2007) 405-409
20. Brenner B., Ilson D.H., and Minsky B.D. Phase I trial of combined-modality therapy for localized esophageal cancer: Escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 22 (2004) 45-52
21. Meluch A.A., Greco F.A., Gray J.R., et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: Final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J 9 (2003) 251-260
22. Ajani J.A., Ilson D., Dougherty K., et al. Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natal Cancer Inst 86 (1994) 1086-1091
23. Choy H., Rodriguez F.F., Koester S., et al. Investigation of Taxol as a potential radiation sensitizer. Cancer 71 (1993) 3774-3778
24. Lineman J., Cook J.A., Fisher J., et al. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natal Cancer Inst 86 (1994) 441-446
25. Edelstein D.J., Rice T.W., Rebecca L.A., et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 18 (2000) 2032-2039
26. Khushalani N., Leichamn C.G., Proulx G., et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: Report of a clinical trial for patients with esophageal cancer. J Clin Oncol 20 (2002) 2844-2850
27. Urba S., Hyman J., Intone M., et al. Pre-operative chemoradiation with cisplatin (CDDP), 5-fluorouracil (5FU), and paclitaxel (Tax), followed by surgery and adjuvant chemotherapy, for loco-regional esophageal carcinoma. [abstract]. Proc Am Soc Clin Oncol 22 (2004) 14s
28. Burmeister B.H., Smothers B.M., Gaskin V., et al. Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomized controlled phase III trial. Lancet Oncol 6 (2005) 659-668